Biogen (NASDAQ:BIIB) Stock Sale Disclosed by Rep. Maria Elvira Salazar

Posted by Brian Himes on Oct 9th, 2026

Representative Maria Elvira Salazar (Republican-Florida) recently sold shares of Biogen Inc. (NASDAQ:BIIB). In a filing disclosed on October 7th, the Representative disclosed that they had sold between $1,001 and $15,000 in Biogen stock on September 24th. The trade occurred in the Representative’s “UBS IRA ACCOUNT” account.

Representative Maria Elvira Salazar also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Citigroup (NYSE:C) on 9/24/2026.
Sold $1,001 – $15,000 in shares of Chubb (NYSE:CB) on 9/24/2026.
Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 9/24/2026.
Sold $1,001 – $15,000 in shares of GE Aerospace (NYSE:GE) on 9/24/2026.
Sold $1,001 – $15,000 in shares of Honeywell International (NASDAQ:HON) on 9/24/2026.
Sold $1,001 – $15,000 in shares of Snowflake (NYSE:SNOW) on 9/24/2026.
Sold $1,001 – $15,000 in shares of FedEx (NYSE:FDX) on 9/24/2026.
Sold $1,001 – $15,000 in shares of Salesforce (NYSE:CRM) on 9/24/2026.
Sold $1,001 – $15,000 in shares of RH (NYSE:RH) on 9/24/2026.
Sold $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 9/24/2026.

Biogen Stock Down 1.7%

Biogen stock opened at $218.43 on Friday. The stock has a market capitalization of $32.27 billion, a PE ratio of 38.66, a price-to-earnings-growth ratio of 2.45 and a beta of 0.09. Biogen Inc. has a twelve month low of $138.00 and a twelve month high of $230.49. The company has a 50 day moving average of $216.95 and a 200-day moving average of $202.10. The company has a quick ratio of 1.26, a current ratio of 1.87 and a debt-to-equity ratio of 0.39.

Biogen (NASDAQ:BIIB – Get Free Report) last announced its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, topping analysts’ consensus estimates of $2.94 by $0.66. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The firm had revenue of $2.74 billion during the quarter, compared to analyst estimates of $2.46 billion. During the same period in the prior year, the business earned $5.47 EPS. The company’s revenue for the quarter was up 3.4% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. On average, equities research analysts anticipate that Biogen Inc. will post 12.41 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on BIIB shares. Needham & Company LLC upped their price objective on Biogen from $255.00 to $256.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Canaccord Genuity Group lifted their target price on Biogen from $245.00 to $248.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Wedbush boosted their target price on Biogen from $201.00 to $215.00 and gave the company a “neutral” rating in a research note on Thursday, July 30th. HSBC upped their price target on Biogen from $165.00 to $175.00 and gave the stock a “reduce” rating in a research report on Thursday, September 10th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $300.00 price target on shares of Biogen in a research note on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $230.00.

View Our Latest Analysis on BIIB

Hedge Funds Weigh In On Biogen

Several hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new position in shares of Biogen during the 2nd quarter worth approximately $3,453,878,000. Orbimed Advisors LLC acquired a new position in Biogen in the first quarter valued at about $11,293,000. Nippon Life Global Investors Americas Inc. acquired a new position in Biogen in the second quarter valued at about $29,648,000. Sector Gamma AS lifted its position in Biogen by 13.2% during the fourth quarter. Sector Gamma AS now owns 85,475 shares of the biotechnology company’s stock worth $15,043,000 after purchasing an additional 10,000 shares during the period. Finally, Handelsbanken Fonder AB grew its stake in Biogen by 12.7% during the second quarter. Handelsbanken Fonder AB now owns 93,236 shares of the biotechnology company’s stock worth $20,145,000 after buying an additional 10,510 shares in the last quarter. 87.93% of the stock is owned by institutional investors.

About Representative Salazar

Maria Elvira Salazar (Republican Party) is a member of the U.S. House, representing Florida’s 27th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.

Salazar (Republican Party) ran for re-election to the U.S. House to represent Florida’s 27th Congressional District. She won in the general election on November 5, 2024.

Maria Elvira Salazar was born in Miami, Florida, and lives in Coral Gables, Florida. Salazar earned an undergraduate degree from the University of Miami in 1983 and a graduate degree from Harvard University in 1995. Her career experience includes working as a television journalist, reporter, and news anchor.

About Biogen

(Get Free Report)

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for serious neurological and neurodegenerative diseases. Its research focuses on conditions including multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, amyotrophic lateral sclerosis and rare neuromuscular disorders.

Biogen’s products include Spinraza (nusinersen) for spinal muscular atrophy, Tysabri (natalizumab) and Tecfidera (dimethyl fumarate) for multiple sclerosis, Qalsody (tofersen) for a genetically defined form of ALS, and Skyclarys (omaveloxolone) for Friedreich’s ataxia.